<i>Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer</i>
Colleen Kelly(Boston Children's Hospital), Kira Bona(Dana-Farber Cancer Institute), Puja J. Umaretiya(The University of Texas Southwestern Medical Center), Sunyu Kang(Harvard University), Leanne Duhaney(Boston Children's Hospital), Anna Revette(Dana-Farber Cancer Institute), Erika Hanson(University of Michigan), Paul Morgan(University of Pittsburgh), Rahela Aziz‐Bose(Harvard University)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
|Journal of Clinical Oncology|2016|754
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679